Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aclaris Therapeutics, Inc. (NASDAQ: ACRS).

Full DD Report for ACRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACRS)

Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan
WAYNE, Pa., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology...
Source: GlobeNewswire
Date: December, 03 2018 07:00
Aclaris Therapeutics beats by $0.20, misses on revenue
Aclaris Therapeutics (NASDAQ: ACRS ): Q3 GAAP EPS of -$1.06 beats by $0.20 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 16:18
Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significa...
Source: GlobeNewswire
Date: November, 06 2018 16:01
Aclaris Therapeutics to Attend Upcoming Investor Conferences
WAYNE, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and im...
Source: GlobeNewswire
Date: November, 02 2018 16:01
Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
WAYNE, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and im...
Source: GlobeNewswire
Date: October, 29 2018 16:01
Daily Insider Ratings Round Up 10/23/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: October, 25 2018 11:49
Aclaris Announces Closing of Public Offering of Common Stock
WAYNE, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatolog...
Source: GlobeNewswire
Date: October, 22 2018 16:01
Premarket Losers as of 9:05 am (10/18/2018)
OPGN   -18%  on announcing common stock offering. More news on: OpGen, Auris Medical Holding, Sealed Air Corporation, Stocks on the move, Top stock market news, , Read more ...
Source: SeekingAlpha
Date: October, 18 2018 09:12
Aclaris prices stock offering at $10.75; shares down 12% premarket
Aclaris Therapeutics (NASDAQ: ACRS ) prices its public offering of 8.645M common shares at $10.75 per share. Underwriters over-allotment is an additional ~1.297M shares. Closing date is October 22. More news on: Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read m...
Source: SeekingAlpha
Date: October, 18 2018 07:01
Aclaris Announces Pricing of Public Offering of Common Stock
WAYNE, Pa., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology ...
Source: GlobeNewswire
Date: October, 17 2018 21:44

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0814.9715.2815.42514.7435238,152
2018-05-1719.4919.6419.8219.45143,736
2017-06-2025.7326.0626.5425.25263,156
2017-06-1925.5625.7626.38525.28291,847
2017-06-1625.0025.4925.9624.76511,777

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14138,781354,68539.1280Short
2018-12-1320,714107,82319.2111Cover
2018-12-125,87432,90517.8514Cover
2018-12-1133,24678,86742.1545Short
2018-12-1023,46859,32139.5610Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACRS.


About Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

Logo for Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

Aclaris Therapeutics, Inc. is a clinical stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology

 

Contact Information

 

 

Current Management

  • Neal Walker / President, CEO
  • Frank Ruffo / CFO
  • Christopher Powala / CCO
  • Neal Walker /

Current Share Structure

  • Market Cap: $600,725,004 - 05/14/2018
  • Issue and Outstanding: 30,901,492 - 03/09/2018

 


Recent Filings from (NASDAQ: ACRS)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ACRS)

Daily Technical Chart for (NASDAQ: ACRS)


Stay tuned for daily updates and more on (NASDAQ: ACRS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACRS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACRS and does not buy, sell, or trade any shares of ACRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/